Benzinga··Vandana SinghMerck Seeks to Expand RSV Antibody Approval Following Positive Phase 3 Trial Results
Merck's RSV antibody Enflonsia shows positive Phase 3 results, supporting FDA expansion plans to protect more at-risk infants from respiratory syncytial virus infection.
MRKGSKmonoclonal antibodyFDA approval